ZLJ-6

ZLJ-6 is a dual COX and 5-LOX inhibitor with oral activity. The IC50 values for COX-1, COX-2 and 5-LOX were 0.73, 0.31 and 0.99 μM, respectively. ZLJ-6 has anti-inflammatory and analgesic activity[1][1].

Product Specifications

CAS Number

[1051931-39-5]

UNSPSC

12352005

Target

COX; Lipoxygenase

Type

Reference compound

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/zlj-6.html

Solubility

10 mM in DMSO

Smiles

CS(=O)(O)=O.CN(C(N)=NC/1=O)C1=C/C2=CC=C(C=C2)S(C)(=O)=O

Molecular Formula

C13H17N3O6S2

Molecular Weight

375.42

References & Citations

[1]Li L, et al. The anti-inflammatory effects of ZLJ-6, a novel dual cyclooxygenase/5-lipoxygenase inhibitor. Eur J Pharmacol. 2009 Apr 1;607 (1-3) :244-50.|[2]Chen L, et al. ZLJ-6, a novel COX/5-LOX inhibitor, attenuates TNF-α-induced endothelial E-selectin, ICAM-1 and VCAM-1 expression and monocyte-endothelial interactions via a COX/5-LOX-independent mechanism. Vascul Pharmacol. 2011 Nov-Dec;55 (5-6) :135-42.